A Safety, Tolerability, Pharmacokinetic, and Efficacy Study of ABY-035/AFO2 Given as Multiple Doses in Sequential Escalating Dose Cohorts in Psoriasis Subjects
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2019
Price : $35 *
At a glance
- Drugs ABY 035 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors Affibody
- 10 Dec 2019 Status changed from not yet recruiting to recruiting.
- 17 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.
- 17 Apr 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.